| Literature DB >> 35163880 |
Nesreen T El-Shamy1,2, Ahmed M Alkaoud3, Rageh K Hussein3, Moez A Ibrahim3, Abdulrahman G Alhamzani4, Mortaga M Abou-Krisha4,5.
Abstract
Heterocyclic compounds, including pyrimidine derivatives, exhibit a broad variety of biological and pharmacological activities. In this paper, a previously synthesized novel pyrimidine molecule is proposed, and its pharmaceutical properties are investigated. Computational techniques such as the density functional theory, ADMET evaluation, and molecular docking were applied to elucidate the chemical nature, drug likeness and antibacterial function of molecule. The viewpoint of quantum chemical computations revealed that the molecule was relatively stable and has a high electrophilic nature. The contour maps of HOMO-LUMO and molecular electrostatic potential were analyzed to illustrate the charge density distributions that could be associated with the biological activity. Natural bond orbital (NBO) analysis revealed details about the interaction between donor and acceptor within the bond. Drug likeness and ADMET analysis showed that the molecule possesses the agents of safety and the effective combination therapy as pharmaceutical drug. The antimicrobial activity was investigated using molecular docking. The investigated molecule demonstrated a high affinity for binding within the active sites of antibacterial and antimalarial proteins. The high affinity of the antibacterial protein was proved by its low binding energy (-7.97 kcal/mol) and a low inhibition constant value (1.43 µM). The formation of four conventional hydrogen bonds in ligand-protein interactions confirmed the high stability of the resulting complexes. When compared to known standard drugs, the studied molecule displayed a remarkable antimalarial activity, as indicated by higher binding affinity (B.E. -5.86 kcal/mol & Ki = 50.23 M). The pre-selected molecule could be presented as a promising drug candidate for the development of novel antimicrobial agents.Entities:
Keywords: ADMET; DFT; antimicrobial activity; drug likeness; molecular docking; pyrimidine molecule
Mesh:
Substances:
Year: 2022 PMID: 35163880 PMCID: PMC8839838 DOI: 10.3390/molecules27030620
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Drug molecules have a pyrimidine ring in their molecular structure.
Figure 2The molecular structure (A) and the optimized structure (B) of the proposed compound.
Figure 3The pattern of HOMO and LUMO frontier molecular orbital surfaces.
The calculated HOMO, LUMO energies and their corresponding quantum chemical parameters.
| Parameter | Symbol | Value | Unit |
|---|---|---|---|
| HOMO Energy | EHOMO | −5.78 | (eV) |
| LUMO Energy | ELUMO | −0.80 | (eV) |
| Energy gap | ΔE | 4.98 | (eV) |
| Ionization potential | I | 5.78 | (eV) |
| Electron affinity | A | 0.80 | (eV) |
| Chemical hardness | η | 2.49 | (eV) |
| Chemical softness | σ | 0.40 | (eV)−1 |
| Electronegativity | χ | 3.29 | (eV) |
| Chemical potential | µ | −3.29 | (eV) |
| Electrophilicity | ω | 2.17 | (eV) |
Figure 4Molecular electrostatic potential (MEP) 3D plot of the investigated molecule.
Occupancy of natural orbitals and hybrids of compound for C,N,O,H,Cl atoms.
| Parameters | Occupancies (e) | Hybrids | Atomic Orbitals % |
|---|---|---|---|
| σ C1-C2 | 1.97901 | sp1.56 | s (39.04%) p (60.92%) d (0.04%) |
| σ C1-C4 | 1.97896 | sp1.56 | s (39.08%) p (60.88%) d (0.04%) |
| σ C1-Cl1 | 1.98611 | sp3.60 | s (21.72%) p (78.10%) d (0.19%) |
| σ C2-C3 | 1.96743 | sp1.75 | s (36.39%) p (63.56%) d (0.04%) |
| σ C2-H8 | 1.97753 | sp2.57 | s (28.00%) p (71.96%) d (0.05%) |
| σ C3-C6 | 1.97158 | sp1.72 | s (36.74%) p (63.22%) d (0.04%) |
| σ C3-H9 | 1.97563 | sp2.61 | s (27.69%) p (72.26%) d (0.05%) |
| σ C4-C5 | 1.96730 | sp1.77 | s (36.09%) p (63.87%) d (0.04%) |
| σ C4-H10 | 1.97771 | sp2.56 | s (28.08%) p (71.87%) d (0.05%) |
| σ C5-H7 | 1.97738 | sp2.68 | s (27.18%) p (72.77%) d (0.05%) |
| σ C6-C31 | 1.96267 | sp2.20 | s (31.28%) p (68.69%) d (0.02%) |
| σ C12-N18 | 1.98760 | sp2.40 | s (29.35%) p (70.56%) d (0.09%) |
| σ C14-O15 | 1.99226 | sp2.07 | s (32.55%) p (67.31%) d (0.13%) |
| σ C26-H28 | 1.98897 | sp2.98 | s (25.13%) p (74.80%) d (0.07%) |
| LP (1) O15 | 1.97587 | sp0.72 | s (58.12%) p (41.86%) d (0.02%) |
| LP (1) O51 | 1.97556 | sp0.72 | s (58.01%) p (41.97%) d (0.02%) |
| σ* C1-Cl1 | 0.03496 | sp3.60 | s (21.72%) p (78.10%) d (0.19%) |
| σ* C4-H10 | 0.01433 | sp2.56 | s (28.08%) p (71.87%) d (0.05%) |
| σ* C31-C32 | 0.03013 | sp2.59 | s (27.83%) p (72.13%) d (0.04%) |
| σ* N39-C41 | 0.07580 | sp1.93 | s (34.09%) p (65.84%) d (0.06%) |
| σ* C47-H50 | 0.01098 | sp2.87 | s (25.85%) p (74.09%) d (0.06%) |
Second-order perturbation theory analysis of Fock matrix as a basis for the NBO analysis between donor and acceptor orbitals of the studied compound.
| Type | Donor(i) | Type | Acceptor(j) | |||
|---|---|---|---|---|---|---|
| π | C12-C13 | π* | C14-O15 | 28.26 | 0.3 | 0.086 |
| π | C5-C6 | π* | C1-C4 | 21.48 | 0.27 | 0.069 |
| π | C5-C6 | π* | C2-C3 | 19.66 | 0.29 | 0.068 |
| π | C38-O51 | π* | C32-C34 | 4.54 | 0.38 | 0.04 |
| π | C12-C13 | σ* | C6-C31 | 3.52 | 0.69 | 0.046 |
| π | C12-C13 | σ* | C31-H33 | 2.01 | 0.67 | 0.034 |
| π | C32-C34 | σ* | C31-H33 | 1.21 | 0.66 | 0.026 |
| π | C38-O51 | π* | C38-O51 | 1.08 | 0.38 | 0.02 |
| π | C32-C34 | σ* | N35-H36 | 0.53 | 0.67 | 0.018 |
| σ | C4-C5 | σ* | C1-Cl11 | 5.48 | 0.84 | 0.061 |
| σ | C3-H9 | σ* | C5-C6 | 4.82 | 1.08 | 0.064 |
| σ | C31-C32 | σ* | C34-N40 | 4.77 | 1.04 | 0.063 |
| σ | C32-C38 | σ* | C32-C34 | 4.29 | 1.27 | 0.066 |
| σ | C1-C2 | σ* | C1-C4 | 4.12 | 1.29 | 0.065 |
| σ | N18-H20 | σ* | C12-C13 | 4.02 | 1.26 | 0.064 |
| σ | C13-C14 | σ* | N16-C26 | 3.16 | 1.01 | 0.051 |
| σ | C12-C13 | σ* | C12-N18 | 3.11 | 1.16 | 0.054 |
| σ | N40-C41 | σ* | N39-C43 | 2.61 | 1.14 | 0.049 |
| σ | N17-C21 | σ* | C12-N17 | 2.19 | 1.24 | 0.047 |
| σ | C38-N39 | σ* | N39-C43 | 1.16 | 1.11 | 0.032 |
| σ | C5-H7 | σ* | C4-C5 | 0.64 | 1.09 | 0.024 |
| σ | C38-N39 | σ* | C43-H44 | 0.51 | 1.21 | 0.022 |
| LP(1) | N16 | π* | C21-O30 | 65.67 | 0.26 | 0.117 |
| LP(1) | N40 | π* | C32-C34 | 45.98 | 0.3 | 0.106 |
| LP(2) | O15 | σ* | C14-N16 | 28.83 | 0.62 | 0.121 |
| LP(3) | Cl11 | π* | C1-C4 | 12.11 | 0.33 | 0.062 |
| LP(1) | N40 | σ* | C47-H49 | 5.59 | 0.64 | 0.059 |
| LP(1) | O51 | σ* | C32-C38 | 2.88 | 1.16 | 0.052 |
| LP(1) | O30 | σ* | N17-C21 | 1.98 | 1.07 | 0.042 |
| LP(2) | O51 | σ* | C43-H44 | 0.91 | 0.67 | 0.023 |
| LP(2) | O51 | π* | C2-C3 | 0.62 | 0.27 | 0.012 |
LP—Lone pair, E(—Stabilization energy, E(i)−E(j)—Energy difference between the donor and acceptor NBO orbitals, F(i,j)—Fock matrix element between i and j NBO orbitals.
The drug likeness profile and ADMET analysis.
| Property | Parameter/Model Name | Predicted Value | Unit |
|---|---|---|---|
| Drug likeness | MW | 432.86 | (g/mol) |
| Drug likeness | HBD | 2 | Numeric |
| Drug likeness | HBA | 10 | Numeric |
| Drug likeness | nRotb | 3 | Numeric |
| Drug likeness | octanol/water coefficient | 2.69 | Numeric (Log Po/w) |
| Absorption | Water solubility | −2.51 | Numeric (log mol/L) |
| Absorption | Intestinal absorption | 68.56 | Numeric (% Absorbed) |
| Absorption | P-glycoprotein I inhibitor | No | Categorical (Yes/No) |
| Absorption | P-glycoprotein II inhibitor | No | Categorical (Yes/No) |
| Absorption | Skin Permeability | −8.98 | Numeric (log Kp) |
| Distribution | VDss (human) | −0.239 | Numeric (log L/kg) |
| Metabolism | CYP1A2 inhibitor | No | Categorical (Yes/No) |
| Metabolism | CYP2C19 inhibitor | No | Categorical (Yes/No) |
| Metabolism | CYP2C9 inhibitor | No | Categorical (Yes/No) |
| Metabolism | CYP2D6 inhibitor | No | Categorical (Yes/No) |
| Metabolism | CYP3A4 inhibitor | No | Categorical (Yes/No) |
| Excretion | Total Clearance | −0.62 | Numeric (log ml/min/kg) |
| Excretion | Renal OCT2 substrate | No | Categorical (Yes/No) |
| Toxicity | AMES toxicity | No | Categorical (Yes/No) |
| Toxicity | Max. tolerated dose (human) | −0.004 | Numeric (log mg/kg/day) |
| Toxicity | hERG I inhibitor | No | Categorical (Yes/No) |
| Toxicity | hERG II inhibitor | No | Categorical (Yes/No) |
| Toxicity | Oral Rat Acute Toxicity (LD50) | 2.746 | Numeric (mol/kg) |
| Toxicity | Oral Rat Chronic Toxicity (LOAEL) | 0.932 | Numeric (log mg/kg_bw/day) |
| Toxicity | Hepatotoxicity | Yes | Categorical (Yes/No) |
| Toxicity | Skin Sensitisation | No | Categorical (Yes/No) |
| Toxicity | Pyriformis toxicity | 0.294 | Numeric (log ug/L) |
| Toxicity | Minnow toxicity | 3.052 | Numeric (log mM) |
Figure 5Bioavailability radar depiction of the two-dimensional molecular structure.
The achieved docking results for the complexes of the studied molecule (C19H21ClN6O4) and standard drug (Trimethoprim) with antibacterial, antimalarial target proteins.
| Antimicrobial Activity | Target Protein | Docked Molecule | Binding Energy (kcal/mol) | Inhibition Constant (µM) | Hydrogen Bonds | Interacting Residues | Bond Distance (Å) |
|---|---|---|---|---|---|---|---|
|
| 3ACX | C19H21ClN6O4 | −7.97 | 1.43 | 4 | ARG171 | 6.43 |
| TYR41 | 5.21 | ||||||
| SER19 | 5.99 | ||||||
| GLN165 | 3.54 | ||||||
| Trimethoprim | −8.09 | 1.18 | 3 | VAL133 | 3.86 | ||
| ASP48 | 3.57 | ||||||
| CYC44 | 4.06 | ||||||
|
| 1VQQ | C19H21ClN6O4 | −6.43 | 19.23 | 4 | ASN159 | 3.66 |
| GLU161 | 3.82 | ||||||
| ASP323 | 3.74 | ||||||
| LYS322 | 3.60 | ||||||
| Trimethoprim | −7.66 | 2.43 | 4 | ASP323 | 4.30 | ||
| ASP323 | 5.00 | ||||||
| GLN 325 | 4.40 | ||||||
| GLU161 | 5.16 | ||||||
|
| 1U72 | C19H21ClN6O4 | −7.00 | 7.4 | 2 | VAL115 | 3.71 |
| ALA9 | 3.80 | ||||||
| Trimethoprim | −7.78 | 1.97 | 3 | GLU30 | 3.95 | ||
| VAL8 | 5.23 | ||||||
| TYR121 | 6.05 | ||||||
|
| 3QGT | C19H21ClN6O4 | −5.86 | 50.23 | 4 | ASN330 | 3.89 |
| GLN327 | 4.24 | ||||||
| ILE357 | 4.62 | ||||||
| ILE357 | 4.63 | ||||||
| Trimethoprim | −5.19 | 156.88 | 5 | GLN327 | 3.65 | ||
| GLN327 | 3.95 | ||||||
| LYS359 | 4.85 | ||||||
| LYS359 | 5.09 | ||||||
| ILE357 | 4.31 |
Figure 63D, 2D representations of the interactions of the studied molecule inside the active sites of the target proteins.